Literature DB >> 8595168

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.

L K Webster1, E J Cosson, K H Stokes, M J Millward.   

Abstract

The effect of the paclitaxel vehicle Cremophor on the pharmacokinetics of doxorubicin and doxorubicinol was studied in two groups of mice given intravenously either 2.5 ml kg-1 Cremophor or saline followed 5 min later by 10 mg kg-1 doxorubicin. In each group three mice were sacrificed at ten time points and doxorubicin and doxorubicinol were measured in plasma by high-performance liquid chromatography (HPLC). With Cremophor present, doxorubicin AUC increased from 1420+/-440 to 2770+/-660 ng h ml(-1) (P<0.05) and doxorubicinol AUC increased from 130+/-76 to 320+/-88 ng h ml(-1) (p<0.05). Neither the terminal elimination half-lives nor the doxorubicinol-doxorubicin AUC ratio changed in the presence of Cremophor, suggesting a lack of a direct effect on drug metabolism. The possibility exists the Cremophor may change the pharmacokinetics of both paclitaxel and other drugs given concurrently.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595168      PMCID: PMC2074445          DOI: 10.1038/bjc.1996.90

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Interaction of cremophor EL with human plasma.

Authors:  M Kongshaug; L S Cheng; J Moan; C Rimington
Journal:  Int J Biochem       Date:  1991

2.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

Authors:  D M Woodcock; S Jefferson; M E Linsenmeyer; P J Crowther; G M Chojnowski; B Williams; I Bertoncello
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

3.  Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.

Authors:  P A Maessen; K B Mross; H M Pinedo; W J van der Vijgh
Journal:  J Chromatogr       Date:  1987-07-03

4.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Authors:  B L Lum; S Kaubisch; A M Yahanda; K M Adler; L Jew; M N Ehsan; N A Brophy; J Halsey; M P Gosland; B I Sikic
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

5.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

Authors:  N L Bartlett; B L Lum; G A Fisher; N A Brophy; M N Ehsan; J Halsey; B I Sikic
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

Review 6.  Clinical pharmacokinetics of paclitaxel.

Authors:  D S Sonnichsen; M V Relling
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 7.  Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals.

Authors:  P Borst; A H Schinkel; J J Smit; E Wagenaar; L Van Deemter; A J Smith; E W Eijdems; F Baas; G J Zaman
Journal:  Pharmacol Ther       Date:  1993-11       Impact factor: 12.310

8.  Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo.

Authors:  K V Speeg; A L Maldonado
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles.

Authors:  F A Sinicrope; P K Dudeja; B M Bissonnette; A R Safa; T A Brasitus
Journal:  J Biol Chem       Date:  1992-12-15       Impact factor: 5.157

10.  The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

Authors:  E Friche; P B Jensen; M Sehested; E J Demant; N N Nissen
Journal:  Cancer Commun       Date:  1990
View more
  12 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.

Authors:  E H Cox; C A Knibbe; V S Koster; M W Langemeijer; E E Tukker; R Lange; P F Kuks; H J Langemeijer; L Lie-A-Huen; M Danhof
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 4.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

5.  A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.

Authors:  D Rischin; L K Webster; M J Millward; G C Toner; S Nawaratne; V Ganju; P Francis; J F Bishop
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

6.  Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.

Authors:  N Cordes; L Plasswilm; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-04       Impact factor: 3.621

7.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Authors:  Meret Martin-Facklam; Jürgen Burhenne; Reinhard Ding; Ruth Fricker; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

Authors:  R Danesi; P F Conte; M Del Tacca
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 9.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemia.

Authors:  Gerald J Fetterly; Urvi Aras; Deepika Lal; Michael Murphy; Patricia D Meholick; Eunice S Wang
Journal:  AAPS J       Date:  2013-04-03       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.